Document Detail


Managing clinical grant costs.
MedLine Citation:
PMID:  19470309     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The rapidly increasing cost of pharmaceutical R&D presents a major challenge for the industry. This paper examines one aspect of that spending, clinical grants, and presents ways that pharmaceutical companies can best manage those expenditures. The first part of the paper examines the role of clinical grant payments as a motivation for clinical trial participation. The second part outlines a number of current management practices for controlling clinical grant costs. Financial compensation is an important matter for many physicians conducting clinical trials, especially those in office-based practices and those conducting phase 4 clinical trials. Since financial considerations are important to most types of investigators, and there is no compelling evidence that paying at high rates insures timely performance or quality data, companies engaging clinical investigators must manage their clinical grant funds as effectively as possible. Sound financial management requires that clinical development professionals appreciate the complex relationship between the pharmaceutical company and the physicians who serve as clinical investigators on that company's clinical trials. Sensible financial management of clinical grants also demands that sponsor companies get the most value for their clinical grant spending. Ultimately, good clinical grant management requires an attitude that combines good business sense with an understanding that pharmaceutical R&D strives to bring to market new drugs that can help patient populations around the world. Investigators are medical contractors in clinical trials, and while they are engaged in their vital research, they are a part of the research process that must be carefully budgeted and managed. Society, pharmaceutical companies, clinical investigators, and patients will reap the benefits of adequately budgeted, and well managed clinical grants.
Authors:
Harold E Glass; Karen Hollander
Related Documents :
21692719 - A therapeutic equivalence program: evidence-based promotion of more efficient use of me...
21761379 - Incorporating population medicine into primary care residency training.
22453049 - Tracking family medicine graduates. where do they go, what services do they provide and...
24522959 - Insights into avicenna's contributions to the science of surgery.
19413919 - The emperors new clothiers.
10717199 - Outcome assessment in radiation oncology.
21766729 - Is there a death with dignity in today's medicine?
25264219 - Field evaluation of an expertise-based formal decision system for fungicide management ...
23397529 - Advances in the evaluation and management of children with portal hypertension.
Publication Detail:
Type:  Journal Article     Date:  2009-02-12
Journal Detail:
Title:  Contemporary clinical trials     Volume:  30     ISSN:  1559-2030     ISO Abbreviation:  Contemp Clin Trials     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-11-03     Completed Date:  2010-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101242342     Medline TA:  Contemp Clin Trials     Country:  United States    
Other Details:
Languages:  eng     Pagination:  221-6     Citation Subset:  IM    
Affiliation:
University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA. h.glass@usp.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Budgets
Clinical Trials as Topic / economics*
Cost Control / methods
Drug Industry / economics*
Health Expenditures*
Humans
Questionnaires
Research Personnel / economics
Research Support as Topic / economics*
United States

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acquiring allergen information from condom manufacturers: a questionnaire survey.
Next Document:  A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials.